Technical Analysis for RDY - Dr. Reddy's Laboratories Ltd

Grade Last Price % Change Price Change
grade B 37.01 -6.02% -2.37
RDY closed down 6.02 percent on Monday, May 20, 2019, on 1.19 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Down Down
See historical RDY trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
200 DMA Support Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Earnings Movers Other 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for RDY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company's specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Health Pharmaceutical Pharmaceutical Industry Pharmaceuticals Pharmaceutical Products Pharmaceutical Industry In China Pharmaceuticals Policy Pain Management Active Pharmaceutical Ingredients Cnx Nifty Pharmacokinetics Economy Of India Chemical Entities Contract Research Services Dr. Reddy's Laboratories Lupin Limited Oncology Therapies
Is RDY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.82
52 Week Low 28.49
Average Volume 160,968
200-Day Moving Average 36.8557
50-Day Moving Average 40.3374
20-Day Moving Average 40.9835
10-Day Moving Average 40.339
Average True Range 0.9502
ADX 25.68
+DI 15.1056
-DI 43.3967
Chandelier Exit (Long, 3 ATRs ) 39.9694
Chandelier Exit (Short, 3 ATRs ) 39.6606
Upper Bollinger Band 43.6085
Lower Bollinger Band 38.3585
Percent B (%b) -0.26
BandWidth 12.810033
MACD Line -0.3786
MACD Signal Line 0.1134
MACD Histogram -0.492
Fundamentals Value
Market Cap 6.14 Billion
Num Shares 166 Million
EPS 1.07
Price-to-Earnings (P/E) Ratio 34.59
Price-to-Sales 2.69
Price-to-Book 3.07
PEG Ratio 0.00
Dividend 0.31
Dividend Yield 0.84%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.29
Resistance 3 (R3) 38.36 38.01 38.07
Resistance 2 (R2) 38.01 37.69 37.97 38.00
Resistance 1 (R1) 37.51 37.48 37.76 37.44 37.93
Pivot Point 37.16 37.16 37.29 37.12 37.16
Support 1 (S1) 36.66 36.84 36.91 36.59 36.09
Support 2 (S2) 36.31 36.63 36.27 36.02
Support 3 (S3) 35.81 36.31 35.95
Support 4 (S4) 35.74